Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, added, “WuXi Biologics’ increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company’s global strategy to work in close proximi...
WuXi Biologics is a global open-access biologics technology platform specializing in the discovery, development, and manufacturing of biologics. Use the CB Insights Platform to explore WuXi Biologics's full profile.
InJanuary 2020, the Group and Bayer jointly announced that WuXi Biologics Germany GmbH will acquire the operations of one of Bayer's final DP manufacturing plants in Leverkusen,Germany, and purchase the associated equipment, in combination with a long-term lease of the building. Based on a manuf...
The market is segmented into End-user(pharmaceutical industry, biologics industry, and medical device industry), Type( Phase iii, Phase ii, Phase iv and BE/BA studies, and Phase), and Geography(North America, Europe, Asia, and Rest of World (ROW)). The growth of the biopharmaceutical ...
In 2012, WuXi opened a chemistry facility in Wuhan and a GMP biologics drug-substance facility in Wuxi city. That year WuXi also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6 anti for rheumatoid arthritis for the Chinese...
Dr. Wu has concurrently been serving as a non-executive director of WuXi Biologics (Cayman) Inc. (stock code: 2269.HK). Dr. Wu obtained a bachelor's degree in molecular biology from University of Science and Technology of China (中國科學技術大學) in the PRC and a Ph.D. degree in ...